Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Goldstein

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Current Diabetes Reports|January 27, 2007
Adipokines and vascular disease in diabetesBarry J Goldstein, Rosario Scalia
The Mount Sinai Journal of Medicine, New York|September 30, 2006
Cardiovascular risk in the spectrum of type 2 diabetes mellitusIntekhab Ahmed, Barry J Goldstein
Endocrine|November 27, 2008
Coronary artery disease screening in patients with diabetesVincent Savarese, Intekhab Ahmed, Barry J Goldstein
Clinical Therapeutics|July 11, 2003
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylureaBarry J Goldstein, Miranda Pans, Cindy J Rubin
Cellular Signalling|December 23, 2003
Integration of multiple downstream signals determines the net effect of insulin on MAP kinase vs. PI 3'-kinase activation: potential role of insulin-stimulated H(2)O(2)Kalyankar Mahadev, Xiangdong Wu, Hiroyuki Motoshima, et al.
Diabetes, Obesity & Metabolism|October 13, 2005
Insulin resistance, diabetes and cardiovascular risk: approaches to treatmentDaniel E Rosenberg, Serge A Jabbour, Barry J Goldstein
Nature Clinical Practice. Cardiovascular Medicine|November 26, 2008
Protective vascular and myocardial effects of adiponectinBarry J Goldstein, Rosario G Scalia, Xin L Ma
Diabetes|January 29, 2005
Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targetsBarry J Goldstein, Kalyankar Mahadev, Mahadev Kalyankar, et al.
Lancet (London, England)|July 1, 2008
Type 2 diabetes: pathogenesis and treatmentMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
The Journal of Physiology|April 15, 2006
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancerHiroyuki Motoshima, Barry J Goldstein, Motoyuki Igata, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Current Diabetes Reports|January 27, 2007
Adipokines and vascular disease in diabetesBarry J Goldstein, Rosario Scalia
The Mount Sinai Journal of Medicine, New York|September 30, 2006
Cardiovascular risk in the spectrum of type 2 diabetes mellitusIntekhab Ahmed, Barry J Goldstein
Endocrine|November 27, 2008
Coronary artery disease screening in patients with diabetesVincent Savarese, Intekhab Ahmed, Barry J Goldstein
Clinical Therapeutics|July 11, 2003
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylureaBarry J Goldstein, Miranda Pans, Cindy J Rubin
Cellular Signalling|December 23, 2003
Integration of multiple downstream signals determines the net effect of insulin on MAP kinase vs. PI 3'-kinase activation: potential role of insulin-stimulated H(2)O(2)Kalyankar Mahadev, Xiangdong Wu, Hiroyuki Motoshima, et al.
Diabetes, Obesity & Metabolism|October 13, 2005
Insulin resistance, diabetes and cardiovascular risk: approaches to treatmentDaniel E Rosenberg, Serge A Jabbour, Barry J Goldstein
Nature Clinical Practice. Cardiovascular Medicine|November 26, 2008
Protective vascular and myocardial effects of adiponectinBarry J Goldstein, Rosario G Scalia, Xin L Ma
Diabetes|January 29, 2005
Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targetsBarry J Goldstein, Kalyankar Mahadev, Mahadev Kalyankar, et al.
Lancet (London, England)|July 1, 2008
Type 2 diabetes: pathogenesis and treatmentMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
The Journal of Physiology|April 15, 2006
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancerHiroyuki Motoshima, Barry J Goldstein, Motoyuki Igata, et al.
Pageof 8